New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
...r Bavituximab II-60
Jenken to Commence Phase II Trial of JBK-122 II-60
Pevion Biotech Initiates Phase I Study of Hepatitis C Vaccine II-61
Releases Phase II Findings of IC41 II-61
6. Recent Industry Activity II-62
Three Rivers Acquires Infergen(R) II-62
Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC's Advisory Committee on Immunization Practices
...gth of visit
ATLANTA, June 24 /PRNewswire/ -- intercell
AG (VSE: ICLL) today announced that the U.S. Cente...able in the United States. IXIARO was developed by intercell
AG; the rights to market and distribute the vaccin... study with JE-VAX(R).
Intercell to Webcast Research & Development Day on Thursday, June 4, 2009
...ENNA and GAITHERSBURG, Md., May 27 /PRNewswire/ -- intercell
AG (VSE: ICLL) today announced that it will webcas...tious disease and the primary investigator for the intercell
Travelers' Diarrhea Phase II clinical trial. Dr. D...rs.
In addition to Dr. DuPont, members of the intercell
management team will make presentations including,...
Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military
... - Exclusive, multi-year contract executed by intercell
and U.S. Department of Defense for purchase of IXI... soon
VIENNA, May 8 /PRNewswire-FirstCall/ -- intercell
AG (VSE: ICLL; OTC Bulletin Board: INRLY) announce...as follows:
Exclusive contract for intercell
to supply DLA with all their requirements for JE v...
Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
... is a result of an excellent collaboration between intercell
and the Walter Reed Army Institute of Research in ...ry
VIENNA, March 31 /PRNewswire-FirstCall/ -- intercell
AG (VSE: ICLL) today announced FDA approval of its...ant contribution towards development of IXIARO and intercell
is very appreciative of this outstanding collabora...
Huntsworth plc Releases Interim Statement on First Quarter 2008
New European clients for Huntsworth Health include Daiichi-Sankyo,
Pfizer and Novartis Vaccines, and global accounts won include Roche,
and Iroko. Our multi-disciplinary business is also
increasing, and whilst most clients still offer new projects and pitches in
one area (advertising o...
Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT
...l/ -- Iomai Corporation
(Nasdaq: IOMI ) today said that it will host a conference call and live
webcast tomorrow to discuss today's announcement that intercell
ICLL) and Iomai have entered into a definitive agreement pursuant to which
Intercell will acquire Iomai for USD 6.60 per share representing a...
Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008
...l Development, Genentech * David P. Meeker, MD, President, LSD Therapeutics, Genzyme * Eszter Nagy, MD, PhD, Vice President, Pre-clinical R&D, intercell
* Steve J. Offord, PhD, Vice President CNS New Products Marketing, Market Access and Business Development, sanofi-aventis * Carlos Plata-Salam...
Intercell to Begin Phase II JE Vaccine Trials in India
... Austrian biotech major, intercell
and its partner Hyderabad-based Biological E. Ltd. announced that they have obtained regulatory clearance to start// a pediatric phase II clinical tri...
Intercell in Medical Technology
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
...ENNA and GAITHERSBURG, Md., May 28 /PRNewswire/ -- intercell
AG (VSE: ICLL) today announced that it has advance...luenza vaccines," stated Thomas Lingelbach, COO of intercell
AG and CEO of intercell
USA. "The recent H1N1 influenza situation certainl...
Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
...orted by PATH
VIENNA, April 7 /PRNewswire/ -- intercell
AG (VSE: ICLL) announced today that a Phase I clin...ase I trial. Under the terms of the collaboration, intercell
will develop the vaccine and make it available at ...is and Otitis media in young children.
Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study
... WILMINGTON, N.C., Jan. 19 /PRNewswire/ -- intercell
AG has retained
Inclinix, Inc., to recruit volunte...ginning in
"We are pleased that intercell
AG has chosen Inclinix as their partner for
the TD...erious adverse events were
USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
... VIENNA, Austria, Dec. 11 /PRNewswire/ -- intercell
AG (VSE: ICLL) today
announced the execution of a ...or Intercell's Pandemic Influenza program.
is developing a Pandemic Influenza Vaccine Patch S...luenza
vaccine, coupled with a single 50-microgram intercell
patch was sufficient to
provide an immune response...
Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program
VIENNA, Austria, Sept. 3 /PRNewswire/ -- Today, intercell
announced the six months follow up data ...sting and future HCV combination treatments.
will follow its development strategy that will als...seen to expand to about EUR
3.5bn by 2006.
Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
... VIENNA, Austria, Aug. 28 /PRNewswire/ -- intercell
AG (VSE: ICLL) today
announced that its collaborat...based on a conserved protein antigen
discovered by intercell
and licensed to Merck & Co., Inc. in 2004 on an
manufacturing and marketing. intercell
is eligible to receive milestone
payments and roya...
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
As previously announced, Iomai and intercell
AG (VSE: ICLL) have
entered into an agreement wher...tered into an agreement with
Intercell AG in which intercell
will acquire Iomai for $6.60 a share.
Some matte... to use;
that the proposed acquisition of Iomai by intercell
does not close or that
the companies may be requir...
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
... - intercell
AG ('Intercell') to acquire Iomai Corporation ('Io...y major shareholders for
approximately 1.7 million intercell
shares (representing approximately four
percent ...chnology in the industry. Through the transaction intercell
gains access to a further product ...
Staphylococcus aureus vaccine development on track ? safe and
immunogenic in Phase I clinicaltrials
... VIENNA, Austria, May 18, 2007 – intercell
“ICLL”) has been informed by ...
increasingly difficult and
Intercell AG is a growing biotechnology company which focuses on
the design and intercell
a growing biotechnology company which focus...
Intercell in Biological Technology
Iomai Stockholders Approve Merger With Intercell Subsidiary
GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai Corporation
(Nasdaq: IOMI ) announced today that its stockholders approved the merger of
Iomai with a wholly-owned subsidiary of Intercell
AG. Approximately 71.6
percent of Iomai's outstanding shares entitled to vote at the special
Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
GAITHERSBURG, Md. and VIENNA, June 19 /PRNewswire-FirstCall/ -- Iomai
Corporation (Nasdaq: IOMI ) announced that its Chief Scientific Officer,
Gregory Glenn, M.D., and Alexander Von Gabain, Ph. D., the Chief Scientific
Officer of Intercell
AG (VSE: ICLL), will speak today at the Biotechnology...
Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
VIENNA, April 2 /PRNewswire/ -- intercell
AG (VSE: ICLL) today announced that its new vaccin... study with JE-VAX(R).
AG is an innovative biotechnology company that des...
Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
... VIENNA, March 31 /PRNewswire/ -- intercell
AG (VSE: ICLL) today announced that it will host a...d Thomas Lingelbach (COO and
Managing Director intercell
Biomedical Ltd., Scotland)
Austr... and an operator will then put you through to the intercell
The presentation will be mad...
Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
... for Q2 2009
VIENNA, March 30 /PRNewswire/ -- intercell
AG (VSE: ICLL) today announced that the U.S. Food ...d certain other markets in Asia and Latin America. intercell
will directly distribute and market IXIARO to the ... study with JE-VAX(R).
Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis
...VIENNA, Austria, Jan. 23 /PRNewswire-FirstCall/ -- intercell
(VSE: ICLL) today announced that the Australian...egulatory approval for the vaccine in any country. intercell
successfully advancing parallel regulator...uinea
and Pacific Islands (trade name JESPECT(R)). intercell
is committed to make
JESPECT(R) available to the A...
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
... FAES FARMA SA (SIBE Spain: FAE) GPC BIOTECH AG (NASDAQ: GPC ) GRIFOLS SA (SIBE Spain: GRF) H LUNDBECK A/S (OMX Nordic Exchange Copenhagen: LUN) intercell
AG (Wiener Bourse, Austria: ICLL) RICHTER GEDEON NYRT (Budapest, Hungary: RICHTBO) STADA ARZNEIMITTEL AG (Frankfurt, Germany: SAZ) ZELTIA SA (SIBE ...
Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
...technology with regard to the use of certain fusion proteins
in the development of a tuberculosis vaccine. The license from SSI includes
access to the intercell
IC31(R) adjuvant. If the development is successful,
sanofi pasteur would manufacture the vaccine commercially.
SSI TB vaccine candidates are recombi...
Intercell in Biological Dictionary
...n... Information about Antigens in the free online English dictionary and encyclopedia. ... Kirin Brewery Introduces Pneumococcal Antigens from intercell
AG, ... by ... The antigens are located on the surface of the red blood cells and the ... in the A+ blood bind the antigens in the B+ blood a...